Promising results from Malaria vaccine
Published: 2013 August 09 10:28:50 (4968 Views)
A malaria vaccine has shown promising results in early stage clinical trials, a study suggests.
Researchers found the vaccine, which is being developed in the US, protected 12 out of 15 patients from the disease, when given in high doses.
The method is unusual because it involves injecting live but weakened malaria-causing parasites directly into patients to trigger immunity.
The research is published in the journal Science.
Lead author Dr Robert Seder, from the Vaccine Research Center at the National Institutes of Health, in Maryland, said: "We were excited and thrilled by the result, but it is important that we repeat it, extend it and do it in larger numbers."
It has been known for several decades that exposure to mosquitoes treated with radiation can protect against malaria.
However, studies have shown that it takes more than 1,000 bites from the insects over time to build up a high level of immunity, making it an impractical method of widespread protection.
Instead, a US biotech company called Sanaria has taken lab-grown mosquitoes, irradiated them and then extracted the malaria-causing parasite (Plasmodium falciparum), all under the sterile conditions.
These living but weakened parasites are then counted and placed in vials, where they can then be injected directly into a patient's bloodstream. This vaccine candidate is called PfSPZ.
To carry out the Phase-1 clinical trial, the researchers looked at a group of 57 volunteers, none of whom had had malaria before.
Of these, 40 received different doses of the vaccine, while 17 did not. They were then all exposed to the malaria-carrying mosquitoes.
The researchers found that for the participants not given any vaccine, and those given low doses, almost all became infected with malaria.
However for the small group given the highest dosage, only three of the 15 patients became infected after exposure to malaria.
Dr Robert Seder said: "Based on the history, we knew dose was important because you needed 1,000 mosquito bites to get protection - this validates that.
"It allows us in future studies to increase the dose and alter the schedule of the vaccine to further optimise it. The next critical questions will be whether the vaccine is durable over a long period of time and can the vaccine protect against other strains of malaria."
Anopheles mosquito Malaria kills about 600,000 people each year and infects more than 200 million
He added that the fact that the vaccine had to be injected into the bloodstream rather than into or under the skin made delivery more difficult.
Commenting on the research, Dr Ashley Birkett, from the Path Malaria Vaccine Initiative, said: "They are clearly very early stage trials in small numbers of volunteers, but without question we are extremely encouraged by the results."
He added that most current vaccine candidates targeted parts of the P. falciparum parasite rather than the whole organism.
"This approach induces a broad response against a lot of different targets on the parasite," he said.
There are currently about 20 malaria vaccine candidates in clinical trials.
The most advanced is called RTS,S/AS01, which has been developed by the pharmaceutical company GlaxoSmithKline, and is in a Phase-3 clinical trial involving 15,000 children in Africa.
According to the latest figures from the World Health Organization, there were an estimated 219 million cases of malaria in 2010 and an estimated 660,000 deaths.
- BBC
Researchers found the vaccine, which is being developed in the US, protected 12 out of 15 patients from the disease, when given in high doses.
The method is unusual because it involves injecting live but weakened malaria-causing parasites directly into patients to trigger immunity.
The research is published in the journal Science.
Lead author Dr Robert Seder, from the Vaccine Research Center at the National Institutes of Health, in Maryland, said: "We were excited and thrilled by the result, but it is important that we repeat it, extend it and do it in larger numbers."
It has been known for several decades that exposure to mosquitoes treated with radiation can protect against malaria.
However, studies have shown that it takes more than 1,000 bites from the insects over time to build up a high level of immunity, making it an impractical method of widespread protection.
Instead, a US biotech company called Sanaria has taken lab-grown mosquitoes, irradiated them and then extracted the malaria-causing parasite (Plasmodium falciparum), all under the sterile conditions.
These living but weakened parasites are then counted and placed in vials, where they can then be injected directly into a patient's bloodstream. This vaccine candidate is called PfSPZ.
To carry out the Phase-1 clinical trial, the researchers looked at a group of 57 volunteers, none of whom had had malaria before.
Of these, 40 received different doses of the vaccine, while 17 did not. They were then all exposed to the malaria-carrying mosquitoes.
The researchers found that for the participants not given any vaccine, and those given low doses, almost all became infected with malaria.
However for the small group given the highest dosage, only three of the 15 patients became infected after exposure to malaria.
Dr Robert Seder said: "Based on the history, we knew dose was important because you needed 1,000 mosquito bites to get protection - this validates that.
"It allows us in future studies to increase the dose and alter the schedule of the vaccine to further optimise it. The next critical questions will be whether the vaccine is durable over a long period of time and can the vaccine protect against other strains of malaria."
Anopheles mosquito Malaria kills about 600,000 people each year and infects more than 200 million
He added that the fact that the vaccine had to be injected into the bloodstream rather than into or under the skin made delivery more difficult.
Commenting on the research, Dr Ashley Birkett, from the Path Malaria Vaccine Initiative, said: "They are clearly very early stage trials in small numbers of volunteers, but without question we are extremely encouraged by the results."
He added that most current vaccine candidates targeted parts of the P. falciparum parasite rather than the whole organism.
"This approach induces a broad response against a lot of different targets on the parasite," he said.
There are currently about 20 malaria vaccine candidates in clinical trials.
The most advanced is called RTS,S/AS01, which has been developed by the pharmaceutical company GlaxoSmithKline, and is in a Phase-3 clinical trial involving 15,000 children in Africa.
According to the latest figures from the World Health Organization, there were an estimated 219 million cases of malaria in 2010 and an estimated 660,000 deaths.
- BBC
0
You May Like These Videos
WATCH: Victims Narrate Ordeal After Being Clobbered By Riot Cops
FLASHBACK: Morgan Tsvangirai Won't Resign Despite Illness 
Police Violently Beat Harare Protesters 
Zimbabwean Man Who Was Shot By Tswana Employer Appeals For HelpComments
There are no comments.
Get Zim Metro Updates Alerts
Big Reads
Schoolgirl drops out after continuous 'sexual abuse' by teacher
by Staff Reporter | 2019 August 13 07:42:33
Mugabe Knows Nothing About The Zimbabwe Constitution: MP
by Staff Reporter | 2016 October 01 08:12:02
Zim's Protesting Graduates Risk Losing Degrees For Expressing Anger Against Mugabe
by Staff Reporter | 2016 October 01 07:57:08
Troubled Harare Giants Dynamos Falls Into Another Deep Crisis
by Own Correspondent | 2016 October 01 07:49:17
Grace Mugabe Grovels At Mnangagwa, Says I Did Not Ask Ubaba To Fire You
by Staff Reporter | 2016 October 01 07:31:48
Mugabe Attacks Mawarire, Claims The Exiled Pastor Failed To Divide Zimbabwe
by Staff Reporter | 2016 October 01 07:19:13
Shock As Local Bank Denies 'Rich' Mugabe's Son Heifty Credit
by Own Correspondent | 2016 September 30 19:14:54Trouble For Police Officers Who Have Been Mercilessly Bludgeoning Protesters
by Staff Reporter | 2016 October 01 07:20:19
Mugabe "Home Coming" And "Thank You" Rally On Cards
by Own Correspondent | 2016 September 23 06:48:24
Prof Moyo Was Dumped By Western Embassies, Claims Mutsvangwa
by Staff Reporter | 2016 September 22 10:08:07Broke RBZ Tracks Down Zimbabweans Living Outside The Country Over Taxi
by Staff Reporter | 2016 September 22 09:16:20
You Are Too Old To Lead, Aging Zim President Mugabe Told
by Own Correspondent | 2016 September 22 07:19:25
Anti-Corruption Commission Loses Property In Failed Probe
by Own Correspondent | 2016 September 20 03:18:19
.jpg)
SHOCKING:14 Year Old HIV-Positive Boy Rapes 7 Pupils
by Own Correspondent | 2016 September 20 00:04:55
